Richard Katz MD delivers specialized consulting in global drug licensing strategy, coordinating parallel regulatory submissions across FDA, EMA, PMDA, and other major authorities. His expertise ensures biopharmaceutical organizations achieve synchronized market authorizations while maintaining compliance across diverse jurisdictions.
Richard Katz MD: Global Drug Licensing Execution
Richard Katz MD consulting optimizes the complex process of multi-jurisdictional drug approvals:
Parallel Submission Strategy
- FDA NDA/BLA with EMA MAA synchronization
• PMDA Japan and Health Canada concurrent filings
• ANVISA Brazil and TGA Australia coordination
Market Access Acceleration
- Orphan drug designation across 5+ jurisdictions
• Mutual Recognition Agreements (MRAs) optimization
• Post-approval variation strategies for lifecycle management
Comprehensive Global Regulatory Intelligence
Richard Katz MD leverages an integrated research ecosystem for international licensing success:
Core Regulatory Databases
FDA Orange Book (U.S. approvals)
EMA European Public Assessment Reports (EPARs)
PMDA Approved Products Database (Japan)
Health Canada Drug Product Database
Supporting Intelligence Platforms
Government Publishing Office (GPO) federal guidance documents
Academic digital commons like Villanueva Digital Commons (clinical trial analyses)
WHO Essential Medicines List precedents
International Conference on Harmonisation (ICH) guidelines
This multi-jurisdictional intelligence framework ensures licensing strategies align with region-specific requirements and harmonized standards.
Cross-Border Dossier Harmonization
Richard Katz MD specializes in bridging regional regulatory differences:
- Common Technical Document (CTD) Module 2-5 alignment
• Regional pharmacovigilance system integration
• Manufacturing site inspection coordination
• Pricing/reimbursement strategy synchronization
Therapeutic expertise spans oncology, rare diseases, CNS disorders, and advanced therapies.
About Richard Katz, MD, MHA
Richard Katz MD, MHA-qualified global drug licensing consultant with proven expertise in multi-jurisdictional regulatory strategy, parallel approvals, and international dossier preparation. Supports biopharma market expansion through compliant global commercialization pathways.
Richard Katz MD represents excellence in global drug licensing consulting. Through sophisticated multi-source intelligence and proven cross-border execution, Dr. Katz enables pharmaceutical organizations to achieve efficient, compliant international market access.